Barclays PLC Anavex Life Sciences Corp. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Barclays PLC holds 155,179 shares of AVXL stock, worth $1.73 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

155,179

Previous 155,179 -0.0%

Holding current value

$1.73 Million

Previous $882,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$4.11 - $7.04 $263,455 - $451,271	64,101 Added 70.38%	155,179 $882,000
Q2 2024 Aug 14, 2024	SELL	$3.39 - $5.02 $71,779 - $106,293	-21,174 Reduced 18.86%	91,078 $385,000
Q1 2024 May 15, 2024	SELL	$4.55 - $6.75 $446,709 - $662,701	-98,178 Reduced 46.66%	112,252 $572,000
Q4 2023 Feb 15, 2024	BUY	$5.04 - $9.95 $251,259 - $496,037	49,853 Added 31.05%	210,430 $1.96 Million
Q3 2023 Nov 07, 2023	SELL	$6.55 - $9.37 $206,809 - $295,848	-31,574 Reduced 16.43%	160,577 $1.05 Million
Q2 2023 Aug 03, 2023	BUY	$7.66 - $9.5 $19,441 - $24,111	2,538 Added 1.34%	192,151 $1.56 Million
Q1 2023 May 04, 2023	BUY	$8.32 - $11.75 $1.49 Million - $2.11 Million	179,613 Added 1796.13%	189,613 $1.63 Million
Q4 2022 Feb 13, 2023	SELL	$7.65 - $14.43 $1.37 Million - $2.59 Million	-179,290 Reduced 94.72%	10,000 $93,000
Q3 2022 Nov 03, 2022	BUY	$8.9 - $12.86 $1.6 Million - $2.31 Million	179,290 Added 1792.9%	189,290 $1.95 Million
Q2 2022 Aug 12, 2022	SELL	$7.31 - $12.84 $803,449 - $1.41 Million	-109,911 Reduced 91.66%	10,000 $100,000
Q1 2022 May 16, 2022	SELL	$9.74 - $17.69 $705,594 - $1.28 Million	-72,443 Reduced 37.66%	119,911 $1.48 Million
Q4 2021 Feb 14, 2022	BUY	$16.88 - $23.31 $3.25 Million - $4.48 Million	192,354 New	192,354 $3.34 Million
Q3 2021 Nov 09, 2021	SELL	$16.82 - $25.75 $214,757 - $328,776	-12,768 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$10.16 - $28.86 $751,870 - $2.14 Million	-74,003 Reduced 85.29%	12,768 $292,000
Q1 2021 May 13, 2021	BUY	$5.17 - $16.13 $69,417 - $216,577	13,427 Added 18.31%	86,771 $1.3 Million
Q4 2020 Feb 11, 2021	SELL	$4.01 - $7.58 $31,366 - $59,290	-7,822 Reduced 9.64%	73,344 $396,000
Q3 2020 Nov 12, 2020	SELL	$3.8 - $5.0 $100,392 - $132,095	-26,419 Reduced 24.56%	81,166 $369,000
Q2 2020 Aug 12, 2020	BUY	$2.62 - $5.2 $104,619 - $207,641	39,931 Added 59.02%	107,585 $529,000
Q1 2020 May 13, 2020	BUY	$2.38 - $5.81 $58,821 - $143,594	24,715 Added 57.56%	67,654 $214,000
Q4 2019 Feb 10, 2020	BUY	$2.31 - $3.14 $50,304 - $68,379	21,777 Added 102.91%	42,939 $111,000
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.9 $14,452 - $25,389	-6,510 Reduced 23.53%	21,162 $67,000
Q2 2019 Aug 14, 2019	SELL	$2.75 - $3.7 $247,027 - $332,363	-89,828 Reduced 76.45%	27,672 $93,000
Q1 2019 May 15, 2019	BUY	$1.68 - $3.42 $197,400 - $401,850	117,500 New	117,500 $358,000
Q3 2018 Nov 14, 2018	SELL	$2.23 - $3.82 $127,176 - $217,854	-57,030 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.08 - $4.26 $101,608 - $208,101	48,850 Added 597.19%	57,030 $149,000
Q1 2018 May 15, 2018	SELL	$2.32 - $3.44 $32,310 - $47,908	-13,927 Reduced 63.0%	8,180 $22,000
Q4 2017 Feb 14, 2018	SELL	$3.12 - $4.94 $3,266 - $5,172	-1,047 Reduced 4.52%	22,107 $71,000
Q3 2017 Nov 14, 2017	BUY	$3.42 - $4.87 $79,186 - $112,759	23,154	23,154 $96,000

Others Institutions Holding AVXL

# of Institutions

155

Shares Held

27.3M

Call Options Held

515K

Put Options Held

838K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $871M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account